These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Photodynamic therapy: treatment of choice for actinic cheilitis? Rossi R; Assad GB; Buggiani G; Lotti T Dermatol Ther; 2008; 21(5):412-5. PubMed ID: 18844720 [TBL] [Abstract][Full Text] [Related]
50. Ingenol mebutate gel for actinic keratosis. Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254 [TBL] [Abstract][Full Text] [Related]
51. Pharmacoeconomic evaluations in the treatment of actinic keratoses. Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871 [TBL] [Abstract][Full Text] [Related]
52. Cosmetic Effects of Ingenol Mebutate Gel in the Treatment of Field-Cancerized Photodamaged Skin. Braun SA; Gerber PA Dermatol Surg; 2015 Nov; 41(11):1328-9. PubMed ID: 26448312 [No Abstract] [Full Text] [Related]
53. Mediators of Inflammation in Topical Therapy of Skin Cancers. Voiculescu VM; Lisievici CV; Lupu M; Vajaitu C; Draghici CC; Popa AV; Solomon I; Sebe TI; Constantin MM; Caruntu C Mediators Inflamm; 2019; 2019():8369690. PubMed ID: 30766448 [TBL] [Abstract][Full Text] [Related]
54. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272 [TBL] [Abstract][Full Text] [Related]
55. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis. Berman B Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis. Stockfleth E; Bastian M Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas. Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709 [TBL] [Abstract][Full Text] [Related]
58. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis. Philipp-Dormston WG Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215 [TBL] [Abstract][Full Text] [Related]
59. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. Bettencourt MS J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570 [TBL] [Abstract][Full Text] [Related]
60. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis. Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]